Key result
NKH477 reduces Ea/Emax by ~52%, improving A-V coupling more than dobutamine in LV systolic dysfunction.
Why the study?
Does NKH477 improve arterial-ventricular coupling and mechanical energy transduction compared to dobutamine in patients with left ventricular systolic dysfunction?
Population
8 patients with left ventricular (LV) systolic dysfunction
Comparison
NKH477 (0.5 μg/kg/min) vs Dobutamine (3 μg/kg/min)
Design
Other
Authors
Loading...
NKH477 may improve coupling efficiency more than dobutamine; hypothesis-generating in small Level 5 study, larger trials needed.
Does NKH477 improve arterial-ventricular coupling and mechanical energy transduction compared to dobutamine in patients with left ventricular systolic dysfunction?
Absolute Event Rate: 52% vs 47%
p-value: p=< 0.05
NKH477 may be a superior alternative to dobutamine for improving arterial-ventricular coupling and mechanical energy transduction in patients with left ventricular systolic dysfunction.
Mori et al. (1994) studied Left ventricular systolic dysfunction (n=8). NKH477 vs. Dobutamine (3 μg/kg/min) was evaluated on Decrease in Ea/Emax (p=< 0.05). NKH477 produced a greater decrease in Ea/Emax (52% vs 47%, p<0.05) and a greater increase in SW/PVA (28% vs 21%, p<0.05) compared to dobutamine in patients with LV systolic dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: